On August 20, 2020, Cao, Ping; Zhang, Chao; Bishop, Michael J. published a patent.Computed Properties of 201811-20-3 The title of the patent was Preparation of novel pyridinylpyrimidines as FGFR inhibitors for the treatment of cancer. And the patent contained the following:
The invention provides the title compounds I [each R1-R5 = (independently) H, F, Cl, Br, alkyl, etc.; R6 = (CH2)0-5CH:CH2, (CH2)0-5CCH, NHCO(CH2)0-5CH:CH2, etc.; Linker = (un)substituted alkyl, COalkyl, CO2alkyl, etc.] or optically pure stereoisomers, solvates, or pharmaceutically acceptable salts thereof with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. E.g., a multi-step synthesis of II, starting from 4-amino-3-nitro-phenol and tert-Bu 3-iodoazetidine-1-carboxylate, was described. Exemplified compounds I were evaluated for FGFR inhibition (data given). These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Computed Properties of 201811-20-3
The Article related to pyridinylpyrimidine preparation fgfr4 inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 201811-20-3
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics